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Abstract
Objective: Genome wide association studies (GWAs) of breast cancer mortality have identified few potential associations.
The concordance between these studies is unclear. In this study, we used a meta-analysis of two prognostic GWAs and a
replication cohort to identify the strongest associations and to evaluate the loci suggested in previous studies. We attempt
to identify those SNPs which could impact overall survival irrespective of the age of onset.
Methods: To facilitate the meta-analysis and to refine the association signals, SNPs were imputed using data from the 1000
genomes project. Cox-proportional hazard models were used to estimate hazard ratios (HR) in 536 patients from the POSH
cohort (Prospective study of Outcomes in Sporadic versus Hereditary breast cancer) and 805 patients from the HEBCS
cohort (Helsinki Breast Cancer Study). These hazard ratios were combined using a Mantel-Haenszel fixed effects meta-
analysis and a p-value threshold of 561028 was used to determine significance. Replication was performed in 1523
additional patients from the POSH study.
Results: Although no SNPs achieved genome wide significance, three SNPs have significant association in the replication
cohort and combined p-values less than 5.661026. These SNPs are; rs421379 which is 556 kb upstream of ARRDC3
(HR = 1.49, 95% confidence interval (CI) = 1.27–1.75, P = 1.161026), rs12358475 which is between ECHDC3 and PROSER2
(HR = 0.75, CI = 0.67–0.85, P = 1.861026), and rs1728400 which is between LINC00917 and FOXF1.
Conclusions: In a genome wide meta-analysis of two independent cohorts from UK and Finland, we identified potential
associations at three distinct loci. Phenotypic heterogeneity and relatively small sample sizes may explain the lack of
genome wide significant findings. However, the replication at three SNPs in the validation cohort shows promise for future
studies in larger cohorts. We did not find strong evidence for concordance between the few associations highlighted by
previous GWAs of breast cancer survival and this study.
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Introduction
Although the incidence of breast cancer has been relatively
stable since 2003, at 157 new cases per 100,000, it remains the
most common cancer in the UK and accounts for 31% of new
cancer cases in women. The latest age-standardised survival rate
for breast cancer in England is predicted to be 85% at 5 years,
falling to 65% at 20 years [1]. Traditionally prognostic informa-
tion is derived from tumour phenotypic characteristics including
tumour size, stage, and grade. These tumour phenotypes and
cancer cell surface receptors such as oestrogen receptor (ER) and
human epidermal growth factor receptor 2 (HER2) are also used
to guide treatment. Although the breast cancer survival rate has
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improved, the response to treatment and longevity of patients is
often unpredictable even between those with similar tumours and
general health. More recently tumour genomic profiling experi-
ments have suggested cancer molecular signatures may give more
accurate prognostic information [2–4]. These signatures may
predict outcome better than conventional histopathology based
risk algorithms but are not in routine clinical use [5].
Familial studies suggest a genetic component for breast cancer
prognosis [6,7]. The familial contribution to prognosis may arise
as a result of the background genotype affecting acquired tumour
characteristics which influence prognosis. Indeed high penetrance
predisposition genes which lead to the consistent development of
specific breast tumour sub-types have been identified [8,9]. Low
penetrance risk SNPs tend to be associated with either ER positive
or ER negative breast cancer but often not both [10–14]. In
addition there may be pharmacogenomic effects of background
genotype on response to cancer treatment. It is anticipated that
genome wide association studies (GWAs) with sufficient sample
size and genetic coverage may lead to novel insights into common
inherited genetic variants which influence prognosis.
In the past few years several GWAs of breast cancer survival
have been reported. These studies have had limited success and
none of them have identified variants that are associated at
genome wide levels of significance [15–19]. While small sample
sizes are likely to be of one of the main factors responsible for the
modest levels of significance and lack of concordance between the
GWAs; small effect sizes, incomplete genetic coverage, and
phenotypic heterogeneity could also contribute and need to be
addressed.
In this study, we used a meta-analysis to combine evidence from
two GWAs consisting of 536 patients from the POSH cohort
(Prospective study of Outcomes in Sporadic versus Hereditary
breast cancer) and 805 patients from the HEBCS cohort (Helsinki
Breast Cancer Study). A further 1523 patients from the POSH
cohort were used to validate the most significant SNPs. With a
combined sample size of 2864 participants, this analysis has 81%
power to detect effects of modest sizes (HR$1.25, p = 0.05) and
with relatively rare SNPs (MAF=10%). The cohorts used in this
analysis have a high incidence of breast cancer related mortality
and well documented tumour and treatment data which make
them ideal for the purpose of exploring genetic factors influencing
prognosis. In addition, these cohorts are similar in terms of their
patient recruitment from regional medical centres, duration of
prospective follow-up, and documentation of breast cancer related
mortality.
Materials and Methods
All participants from POSH and Helsinki gave written informed
consent, all were female. The POSH study received approval from
the South and West Multi-centre Research Ethics Committee
(MREC 00/6/69). The Helsinki breast cancer study received
approval from the Ethical Committee of the Departments of
Oncology and Obstetrics and Gynaecology, Helsinki University
Central Hospital.
Breast cancer patients and genotyping
Breast cancer cases were selected from the POSH study and the
Helsinki breast cancer family Study (HEBCS). POSH study
participants were diagnosed with invasive breast cancer and were
aged forty or younger at diagnosis, the mean age at diagnosis in
this cohort is 36 years. Recruitments to the POSH cohort were
made between January 2000 and January 2008 from oncology
clinics across the UK and the majority (98%) of patients presented
symptomatically. The recruitment, data collection and follow up
procedures for the POSH study participants are described in detail
elsewhere [20].
The HEBCS samples were collected in Helsinki, Finland and
are representative of breast cancer case series at the recruitment
centre during the collection periods (unselected sporadic and
familial cases collected between 1997 and 2004). All of the cases
used in the meta-analysis had histopathological and survival data.
Detailed information on the patient series and data collection has
previously been published [21]. The mean age at diagnosis was
56.8 years.
Stage 1 discovery dataset
In stage-1, 574 participants from the POSH study were selected
for the discovery phase of the analysis aimed at hypothesis
generation [20]. In keeping with a recent GWAS which identified
five new breast cancer susceptibility loci by enriching cases by
recruiting individuals with family history of breast cancer [22],
Table 1. Clinical characteristics of Study participants from the discovery and replication sets.
Study
Number of breast
cancer deaths
Total number
of Breast cancer
patients
Estrogen Receptor
(ER) status-
Negative (%)
Average age
at Diagnosis
(±SD)
Follow-up time
in years (±SD) N-stage M-stage T-stage
POSH stage-1
(Discovery)
236 536 370 (69.2%) 35.7 (3.8) 4.1 (2.0) N0–248
N1–262
NA-26
M0–481
M1–50
NA-5
T1–227
T2–207
T3–20
T4–31
NA-51
HEBCS
(Discovery)
301 805 230 (30.0%)
NA-39
56.8 (12.4) 7.2 (2.9) N0–338
N1–446
NA-21
M0–740
M1–57
NA-8
T1–390
T2–304
T3–50
T4–47
NA-14
POSH stage-2
(Replication)
221 1415 362 (23.7%) 35.8 (3.5) 5.2 (1.7) N0–705
N1–810
NA-8
M0–1506
M1–18
NA-1
T1–692
T2–494
T3–49
T4–34
NA-254
HEBCS: Helsinki Breast Cancer Study; NA= not available, HER2 =Human Epidermal Growth Factor Receptor 2, N-stage =metastasis to lymph node, M-stage =metastasis.
doi:10.1371/journal.pone.0101488.t001
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sample selection for stage-1 utilised an ‘‘extreme phenotype’’
approach, this included selection of triple negative cases genotyped
in a collaboration aimed at risk associated SNPs in triple negative
breast cancer [11] and a second group enriched for exceptionally
short survival genotyped as described previously [23]. We
observed 236 breast cancer specific deaths in the POSH discovery
set patients.
In HEBCS, 805 cases were selected from the patient series
described earlier [22], including 423 unselected cases collected
between years 1997 and 2000 as well as 140 cases collected
between years 2001 and 2004, with 242 additional familial cases.
The GWAS series was specifically enriched for cases with reduced
survival, in the form of distant metastasis or death at the time of
the initiation of the study in 2008, resulting in 301 breast cancer
specific deaths at the time of analysis.
Stage-2 replication Samples
A further 1523 breast cancer patients from the POSH study
[20] unselected for any survival differential were used for
replication in stage-2. At stage 2, there were 293 breast cancer
specific deaths.
Genome wide genotyping
Genotyping of 574 POSH phase-1 breast cancer cases was
conducted using the Illumina 660-Quad SNP array. Genotyping
was conducted in two separate batches at two locations. The Mayo
Clinic (Rochester, Minnesota, USA) genotyped 274 triple negative
breast cancers (negative for ER, PR and HER2) [11]. The
remaining 300 POSH patients were genotyped at the Genome
Institute of Singapore (GIS), National University of Singapore;
these were selected based on either short duration of breast cancer
specific survival (,2 years) or long duration of breast cancer
specific survival (.4 years). In order to ensure complete
harmonisation of genotype calling, the intensity data from GIS
and MAYO were combined and the genotyping module of
Illumina’s Genome Studio software was used to generate
genotypes. A GenCall threshold of 0.15 was selected and the
HumanHap660 annotation file was used. Of the 300 samples
genotyped in Singapore, 3 were excluded from analysis because
they had sample call rates lower than 95%. No individuals among
the two hundred and seventy four triple negative cohort genotyped
at the Mayo clinic were excluded from analysis based on poor call
rate. The genotyping accuracy for SNPs genotyped by GIS and
Mayo were over 99%.
Genotyping of the HEBCS samples was conducted using the
Illumina 550 platform as previously described [24]. SNP quality
control (QC) measures were implemented using Plink. The initial
sample size of 832 was reduced to 805, following quality control
measures to remove patients with; unidentified affectation status
and gender discordance (n = 6), familial relationships and poor
SNP call rate (,95% n=18), and missing phenotype information
(n= 1). Genotypes were determined using the Genome Studio, a
GenCall threshold of 0.15, and the HumanHap550-duo v3
annotation file.
Further quality control of the genotypic data from POSH and
HEBCS was used to exclude rare SNPs with a MAF #0.01, and
SNPs with significant deviation from Hardy-Weinberg equilibrium
(HWE) p-value#0.0001. To select SNPs for generation of pairwise
identity by state (IBS) estimates, we used plink to perform genome
wide linkage disequilibrium (LD)-based pruning with an r2 cut-off
of 0.5 and a window of 50 SNPs. Multi-dimensional scaling (MDS)
plots were generated on the basis of a square matrix of IBS values
between all pairs of individuals. To act as a reference, individuals
with known African, Asian, and Caucasian ancestry from
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HapMap were also used for the MDS analysis [25]. The MDS
analysis excluded 35 cases from POSH and no cases from Helsinki
whose genotypes did not concur with a European ancestry.
Statistical Analysis
We used GenABEL [26] in R.2.14.0 environment to perform
survival analysis using post-QC genome wide SNP data. Follow-up
time was calculated as the difference between the date of diagnosis
of breast cancer and the date of death due to breast cancer or the
date of last follow-up if still alive and right-censored at 10 years.
Distant disease free interval was calculated as the time from
diagnosis to occurrence of metastasis. We excluded patients with
contralateral or ipsilateral cancers for testing association with
distant disease free interval. All the Cox-proportional hazard
models were adjusted for ER-status. Kaplan-Meier plots were
generated using STATA v11.0 and IBM SPSS statistics 19.
Mantel-Haenszel Fixed effects meta-analysis was performed using
the metan module in STATA v11.0 [27]. For multivariate models
we used ER-status, metastasis stage (0 or 1), nodal stage (1 = no
nodes positive, 2 = 1–3 nodes positive, 3 =more than 3 nodes
positive) and tumour size (centimetres) as covariates.
Cochran’s Q-statistic and the resultant p-value was used to
detect heterogeneity in association estimates between POSH and
HEBCS. Genome wide meta-analysis was performed using
MetABEL [28].
Genome wide imputation and meta-analysis
We imputed genome wide SNP information in POSH and
HEBCS based on European phase 1 and release version 3
haplotypes. The reference haplotypes are derived from the 1000
genomes project which is the most comprehensive catalogue of
human genetic variation including SNP, Indels and CNVs.
Quality control measures applied to imputed data included
excluding SNPs with HWE p-value,161026, MAF ,5%; and
genotyping call rate ,90% and individuals call rate ,90%.
Genome wide survival analysis of imputed information was
performed in R-2.14.0 using GenABEL. Meta-analysis of results
from GenABEL was performed using MetABEL. For imputing
data we used MACH (http://www.sph.umich.edu/csg/abecasis/
MACH/index.html). We used VCFtools - v0.1.9.0 to generate
plink format files from output files generated by MACH. The
reference haplotypes for 1000 genomes project were downloaded
from MACH software’s download page. We used Phase I version
3 European reference haplotypes for imputation analysis.
Manhattan and Regional plots
Manhattan and QQ-plots were generated in R using the plot
command. Regional plots were generated using LocusZoom [29].
Sample size calculations
Sample size calculations were performed in R.2.14.2 using
survSNP package. The event rate used for power calculations was
0.29 and a two-sided alpha of 0.05 was applied.
Gene Expression variation by SNP
We used Genevar 3.2.0 to study variation in expression levels by
SNP genotypes available from the MuTHER pilot project while
using NCBI Build 36 Ensembl 54 as reference [30]. Twin pairs
were divided into two groups of unrelated individuals. Expression
data from Lymphoblastoid cell lines are reported here. In addition
we used SNP and CNV annotation database (scandb) [31] that
uses the lymphoblastoid cell line expression data derived from 90
HapMap CEU samples in trios [32].
Prediction of transcription factor binding site changes
The putative changes on transcription factor binding sites
caused by the variants were predicted in silico with MatInspector
Figure 1. Manhattan plot of results from genome wide meta-analysis of POSH stage-1 and HEBCS hazard ratios and 95%
confidence intervals. The 25 most associated SNPs are highlighted in green.
doi:10.1371/journal.pone.0101488.g001
Role of SNPs in Breast Cancer Prognosis
PLOS ONE | www.plosone.org 5 December 2014 | Volume 9 | Issue 12 | e101488
within Genomatix software suite v2.5 (Genomatix Software
GmbH) [33].
Results
POSH stage-1 and HEBCS meta-analysis
Genome wide genotype data were available from 536Caucasian
participants of the POSH study and 805 Caucasian participants of
the HEBCS study. A total of 475,141 SNPs with observed
genotypes were available for meta-analysis in both the studies after
excluding SNPs based on QC criteria. In stage-1 we used fixed-
effects meta-analysis to pool hazard ratio estimates from the 536
POSH and 805 Helsinki breast cancer patients (Table 1). In the
two study meta-analysis we found five SNPs which were associated
at p-values lower than 9.961026 (Table 2, Figure 1). The 25 most
associated loci were selected for replication in POSH stage-2
patients. For loci with more than one SNP associated with survival,
the most significant SNP and any other SNP(s) from the same
locus which were not in high LD with the lead SNP (r2,0.6) were
selected for follow up in stage-2 (Table 3).
Replication testing in POSH stage-2 samples
A total of 18 SNPs with independent association signals were
tested for replication in POSH stage-2 validation samples
(n = 1523). One SNP demonstrated high duplicate error rate (.
8%) and was excluded from analysis. Of the 18 SNPs which were
formally tested for replication, two demonstrated replication
signals in the validation cohort. Nine of the eighteen SNPs which
were tested for replication were observed to be associated in the
same direction as in the POSH and HEBCS meta-analysis. In the
stage-1 and stage-2 meta-analysis the strongest association signal
was observed at rs421379. The minor allele of rs421379 is found
to be associated with a higher risk of breast cancer related death
(HR (95% CI) = 1.49 (1.27–1.75), p = 1.161026) (Figure 2). The p-
value for Cochran’s heterogeneity test Q-statistic was not
indicative of heterogeneity in meta-analysis estimate (p = 0.09).
This variant was previously identified as the most significantly
associated variant in a two stage GWAs for breast cancer survival
in early onset cases from POSH. A weak replication signal in
HEBCS allowed this SNP to be identified as the most strongly
associated variant in this study too (Figure 2). The second most
significant variant was located at 10p14, where the minor allele of
rs12358475 was associated with protective effect on breast cancer
mortality (HR (95% CI) = 0.75 (0.67–0.75), p = 1.861026)
(Figure 3). We observed another strong association with
rs1728400 which is 113.6 kb upstream of the FOXF1 locus
(Table 3). In addition, the three SNPs (rs421379, rs12358475 and
rs1728400) were also associated with distant disease free survival in
the same direction as those observed for overall survival times,
although none of these reached a genome wide level of significance
(Table 4).
Genome wide imputation and meta-analysis
Following quality control of imputed data we had 7105428
SNPs available (maf $5%) in POSH stage-1 patients and 7353135
SNPs available (maf $5%) in the HEBCS study. In the two study
meta-analysis we had close to 6.5 million SNPs available for meta-
analysis. We did not identify any novel SNPs as associated with
survival at p-values smaller than those observed using genotyped
SNPs.
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Figure 2. Kaplan-Meier plots depicting breast cancer related survival in response to rs421379 genotypes in pooled POSH stage-1,
HEBCS and POSH stage-2 samples.
doi:10.1371/journal.pone.0101488.g002
Figure 3. Kaplan-Meier plots depicting breast cancer related survival in response to rs12358475 genotypes in pooled POSH stage-
1, HEBCS and POSH stage-2 sample.
doi:10.1371/journal.pone.0101488.g003
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Gene Expression variation by SNP in publically available
database
We queried the Genevar 3.2.0 and SNP and CNV annotation
database (scandb) to identify Cis or Tran’s eQTL effects resulting
from rs12358475, rs421379 and rs1728400. No associations of
rs12358475 and rs1728400 with expression of any nearby genes
were noticed in Genevar. In scandb too there were no strong
trans-effect associations observed with rs12358475 and rs1728400.
In Scandb we observed that rs421379 had impact on expression of
ABCD1 (p = 1610–5) and RAB34 (p = 9610–5).
Univariate associations of most associated SNPs with N-
stage, M-stage, T-stage and ER-status
In univariate analysis we did not observe any strong associations
of rs12358475 with ER-status, N-stage, M-stage and T-stage. A
nominally significant association with N-stage did not survive
correction for multiple testing (Table 5). The SNP rs1728400
demonstrated weak associations with M-stage and T-stage
(Table 5). No significant association of rs421379 with any of the
clinical variables were observed.
Strength of association of SNPs most associated with
survival in multivariate models
In pooled analysis involving the discovery and replication
samples we observed a slight decrease in the strength of association
at the rs421379 and rs12358475 variants. A prominent decline in
association statistics at the rs1728400 variant was observed. The
HR’s for rs421379 and rs12358475 after adjusting for N-stage, M-
stage, ER-status, and tumour size were 1.41 (1.15–1.72), p = 0.001
and 0.85 (0.75–0.97), p = 0.01. The observed HR for rs1728400
was 1.04 (0.94–1.15) p = 0.46.
Discussion
In this study we report a genome wide meta-analysis for
identifying genetic variants associated with breast cancer related
mortality. In combined meta-analysis involving 2864 individuals
the strongest associations that we have identified locate to three
SNPs at chromosomes 5, 10 and 16. We have previously discussed
the potential biochemical pathways by which rs421379 could
impact survival times [19]. It is important to note that the previous
GWAs study that we had undertaken was performed exclusively in
early onset cases alone. As such the findings from the current study
are potentially important as these suggest a wider role for this
variant in altering survival times in older breast cancer patients.
We did not observe any significant effect of rs12358475 and
rs421379 on clinical factors associated with breast cancer mortality
suggesting that fluctuations in levels of clinical variables could be a
by-product of disease rather than being driving factors.
rs12358475 is intergenic between ECHDC3 (64 kb down-
stream) and C10orf47 (16 kb upstream), and 113 kb upstream of
UPF2. ECHDC3 encodes enoyl CoA hydratase domain contain-
ing 3 which has been described as a new inhibitor of mitochondrial
fatty acid oxidation [34]. Although the clinical significance of this
protein is not clear, it has been found to be differentially expressed
in different breast cancer subtypes in mouse models [35].
ECDHC3 has also been shown to be differentially expressed in
acute coronary syndrome [36]. UPG2 is involved in both mRNA
nuclear export and mRNA surveillance and initiates nonsense-
mediated mRNA decay (NMD) [37]. rs12358475 is predicted to
disrupt a binding site for transcription factors ETS1 and NFAT.
ETS-1 is overexpressed in human breast cancer and this is
indicative of poorer prognosis [38–40].
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rs1728400 lies close to the FOXF1 locus which is a putative
tumour suppressor gene. This variant has previously been
associated with oesophageal adenocarcinoma along with other
SNPs close to rs1728400 which demonstrated even stronger
associations [41]. As such if rs1728400t has a replicable impact on
breast cancer prognosis then it could act via a different set of
transcription factors than those activated in oesophageal carcino-
ma.
Although the study reported here is not the largest study
undertaken for identifying common variants associated with breast
cancer mortality [15,16], it has several methodological strengths. It
is the first study to Meta-analyse associations of common genetic
variants with breast cancer related mortality on a genome wide
level across two independent prospective studies of breast cancer
patients. Further both POSH and HEBCS are prospective studies
of breast cancer patients who were recruited in similar clinical
settings and both cohorts have relatively high breast cancer specific
mortality. As such, heterogeneity between causes of death is
reduced in the meta-analysis. With respect to potential tumour
phenotypic heterogeneity both studies were not selected for
specific breast tumour sub-types so this remains a potential
methodological problem if the effect of SNPs relates to a particular
tumour sub-type or a particular modality of treatment.
It was encouraging to note that 9 off the 18 SNPs which we had
marked for replication testing were associated in the same
direction as in the discovery set. Furthermore 4 of the 18 SNPs
which were tested for replication had previously been identified as
amongst the top 50 associations in GWAs of breast cancer
mortality in early onset patients. rs11723068, rs11491815,
rs421379 and rs1578790 were the first, fourth, eighteenth and
20th most strongly associated SNPs among the top 50 association
[19].
Although previous studies have not described any SNPs as
irrevocably associated with survival at genome wide levels of
significance [15,18], we attempted to test associations of the most
significant SNPs from these studies. None of the 10 SNPs which
Azzato et al [15] tested for replication in the SEARCH study were
associated at p-values#0.05 in the POSH and HEBCS meta-
analysis results. The strongest replication signal we identified was
with rs17299684 (HR=1.15, p= 0.07). Similarly the two SNPs
highlighted by Shu et al [18] as potentially associated with survival
in the Chinese population, were not associated in our meta-
analysis (rs3784099, HR=0.94, P = 0.37 and rs9934948,
HR=1.09, P= 0.32). The association of SNP rs3803662
(TOX3), highlighted by Fasching et al [16], as potentially
associated with breast cancer specific survival did not replicate
in our meta-analysis (HR=0.90, p = 0.09). The lone SNP
highlighted by Azzato et al [17], as associated with survival in
ER-negative patients was not available in the genome wide
genotyped or imputed data, further no proxies at r2$0.6 were
identified based on HapMap phase 3 data. So unfortunately
replication of this SNP could not be tested in our study.
Future studies with a similar ascertainment framework but with
larger sample size, detailed tumour sub-type phenotyping and
similar treatment modalities will be required to allow sub-type
specific patient cohorts to be used for discovery and validation. A
more detailed search for variants with MAF ,0.05 may be
necessary to fully comprehend the extent of intrinsic host genetic
factors in determining breast cancer prognosis.
The main strengths of this study are the high genetic coverage
achieved by using the Illumina 550 K and Illumin660 K chips in
the Helsinki and POSH studies respectively. In addition we have
also performed comprehensive imputation of common genetic
variation (maf .=5%) based on the LD patterns in the 1000
genomes project. We had sufficient statistical power to detect
genetic variants which were associated with survival at HR$1.23
while studying SNPs with maf $10%. Future studies using well
annotated collaborative samples will be needed to perform sub-
type specific analysis and replication to detect small effect sizes.
Such a strategy has the potential to identify multiple genetic
variants which are associated at HRs lower than 1.20. However a
trade-off between the increases in effect sizes that may result from
studying associations in specific homogeneous sub-groups may
mitigate smaller sample sizes.
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